EMAPLUG is the first and only recombinant human thrombopoietin for restoring platelet level.

EMAPLUG contains 1 ml of a solution of 15,000 units of recombinant human thrombopoietin.

EMAPLUG promotes the increase in the number of platelets at 4 or 5 day after the first administration with reaching their peak level at 12 or 13 day.


  • Treatment of thrombocytopenia induced by chemotherapy in patients with solid tumor,
  • Emaplug therapy is recommended for patients with platelet counts below 50 × 109 / l or in cases when the physician considers necessity to increase the platelet count.

How supplied: solution for injection 1 ml.

Sales markets